An update on the progress made in CAR T-cell therapy in India

Gaurav Narula, MD, Tata Memorial Center, Mumbai, India, provides an update on progress made in the CAR-T space in India. Dr Narula highlights the approval of actalycabtagene autoleucel (Actaly-cel™) for treating acute lymphoblastic leukemia (ALL) in patients over 15 years of age, with an ongoing pediatric investigation in a Phase Ib/II trial (CTRI/2023/03/050689). Additionally, a Phase II trial (CTRI/2022/03/041162) has been initiated to investigate varnimcabtagene autoleucel (var-cel) in relapsed/refractory (R/R) B-cell malignancies and a Phase I trial is being conducted to assess PRG1801 in multiple myeloma (MM). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.